검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Dexamethasone or equivalent (Dexamethasone or equivalent) Merck Sharp & Dohme LLC·Acute Lymphoblastic Leukemia ORR 57.7% |
|---|---|
Overview Program | Dexamethasone or equivalent |
Overview Company | Merck Sharp & Dohme LLC |
Overview Modality | ANTIBODY |
Overview Target | Acute Lymphoblastic Leukemia |
Overview Indication | Ovarian Cancer; Fallopian Tube Cancer |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | targets B-cell maturation antigen |
PK/PD Species | Rat, nitric oxide production, and NF-κ, B modulation. |
PK/PD Animal (cat.) | Rat |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Rat, nitric oxide production, and NF-κ, B modulation. |
Toxicology Animal (cat.) | Rat |
Toxicology Major finding | Modulation of NF-κB and cytokine signaling by Cordia dichotoma and Cordia myxa attenuates methotrexate-induced pulmonary inflammation and oxidative injury in rats.. Methotrexate (MTX) is a widely used anticancer and immunosuppressive agent, but its clinical use is limited by lung injury associated with oxidative stress, inflammation, and fibrosis. Leaves of Cordia dichotoma and Cordia myxa t… |
Clinical Primary efficacy | ORR 57.7% |
Clinical ORR | 57.7% |
Clinical PFS | 11.1 |
Clinical OS | 17.6 |
Clinical Result source | ClinicalTrials.gov NCT04191616 |
Clinical Data Tier / Score | A · 68 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Dexamethasone or equivalent (Dexamethasone or equivalent) Merck Sharp & Dohme LLC·Acute Lymphoblastic Leukemia ORR 57.7% |
|---|---|
Overview Program | Dexamethasone or equivalent |
Overview Company | Merck Sharp & Dohme LLC |
Overview Modality | ANTIBODY |
Overview Target | Acute Lymphoblastic Leukemia |
Overview Indication | Ovarian Cancer; Fallopian Tube Cancer |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | targets B-cell maturation antigen |
PK/PD Species | Rat, nitric oxide production, and NF-κ, B modulation. |
PK/PD Animal (cat.) | Rat |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Rat, nitric oxide production, and NF-κ, B modulation. |
Toxicology Animal (cat.) | Rat |
Toxicology Major finding | Modulation of NF-κB and cytokine signaling by Cordia dichotoma and Cordia myxa attenuates methotrexate-induced pulmonary inflammation and oxidative injury in rats.. Methotrexate (MTX) is a widely used anticancer and immunosuppressive agent, but its clinical use is limited by lung injury associated with oxidative stress, inflammation, and fibrosis. Leaves of Cordia dichotoma and Cordia myxa t… |
Clinical Primary efficacy | ORR 57.7% |
Clinical ORR | 57.7% |
Clinical PFS | 11.1 |
Clinical OS | 17.6 |
Clinical Result source | ClinicalTrials.gov NCT04191616 |
Clinical Data Tier / Score | A · 68 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교